STAGE IB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Clinical trials for STAGE IB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy offers hope for rare skin cancer patients
Disease control Recruiting nowThis study tests a new combination treatment for a rare type of skin lymphoma called erythrodermic cutaneous T-cell lymphoma (CTCL). The treatment combines a light-based blood therapy (ECP) with a targeted antibody drug (mogamulizumab) to kill cancer cells and boost the immune sy…
Matched conditions: STAGE IB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New study aims to decode cancer drug rash mystery
Knowledge-focused Recruiting nowThis study looks at a common skin rash caused by the cancer drug mogamulizumab in people with mycosis fungoides or Sezary syndrome (types of blood cancer). The rash can look like the cancer itself, leading doctors to stop treatment too early. Researchers want to learn how to tell…
Matched conditions: STAGE IB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated May 26, 2026 05:29 UTC